Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013
Brief Summary: This protocol posting deals with objectives \& outcome measures of the extension phase up to Month 48. The objective of the extension study is to evaluate the long-term immunogenicity of the HPV 16/18 L1 VLP AS04 vaccine (for all subjects in the HPV Vaccine Group) by enzyme-linked immunosorbent assay (ELISA). The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT00196924).

The long-term follow-up study will be blinded until the primary study is unblinded and will be open for all visits subsequent to unblinding of primary study HPV-013 (NCT00196924). During the open phase, only subjects who received the HPV-16/18 VLP/AS04 vaccine during the primary study will continue their participation in the follow-up study until Month 48. Subjects in the Control group (Havrix®) will attend one further visit as their last study visit.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18 vaccine (Cervarix™) | Arm Label: Aimmugen Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Aimmugen™ | Intervention Type: BIOLOGICAL; Name: HPV-16/18 vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Aimmugen™; Assigned to Arm(s): Aimmugen Group
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: Gardasil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 1 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 2 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: Comparator: octavalent HPV Vaccine - dose formulation 3 | Intervention Type: BIOLOGICAL; Name: Comparator: Gardasil; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 1; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 2; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: Comparator: octavalent HPV Vaccine - dose formulation 3; Assigned to Arm(s): 4
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™ | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™; Assigned to Arm(s): Havrix Group
D: Arm Label: Low-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: Mid-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: High-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: Gardasil; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: GARDASIL, Biological: Experimental: V503 | Intervention Type: BIOLOGICAL; Name: Comparator: GARDASIL; Assigned to Arm(s): Gardasil | Intervention Type: BIOLOGICAL; Name: Experimental: V503; Assigned to Arm(s): Gardasil, High-dose V503, Low-dose V503, Mid-dose V503

Answer: C